News
VCEL
59.45
+0.71%
0.42
Vericel price target raised to $68 from $55 at Stephens
TipRanks · 1d ago
Vericel Is Maintained at Overweight by Stephens & Co.
Dow Jones · 1d ago
Vericel Price Target Raised to $68.00/Share From $55.00 by Stephens & Co.
Dow Jones · 1d ago
Stephens & Co. Maintains Overweight on Vericel, Raises Price Target to $68
Benzinga · 1d ago
Vericel Is Maintained at Buy by Truist Securities
Dow Jones · 2d ago
Vericel Price Target Raised to $65.00/Share From $52.00 by Truist Securities
Dow Jones · 2d ago
Truist Securities Maintains Buy on Vericel, Raises Price Target to $65
Benzinga · 2d ago
Weekly Report: what happened at VCEL last week (1102-1106)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), Humana (HUM) and Vericel (VCEL)
TipRanks · 5d ago
Vericel Q3 Earnings Call Highlights
NASDAQ · 5d ago
Vericel price target raised to $65 from $52 at Truist
TipRanks · 5d ago
Vericel Price Target Raised to $75.00/Share From $72.00 by HC Wainwright & Co.
Dow Jones · 5d ago
Vericel Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $75
Benzinga · 5d ago
Vericel price target raised to $75 from $72 at H.C. Wainwright
TipRanks · 5d ago
Vericel Corporation Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
NASDAQ · 6d ago
Verical Shares Rise After Higher 3Q Profit, Guidance Increase
Dow Jones · 6d ago
Vericel Up Over 17%, On Track for Largest Percent Increase Since November 2022 -- Data Talk
Dow Jones · 6d ago
Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday
Benzinga · 6d ago
Vericel Q3 2026 Earnings Call Transcript
Benzinga · 6d ago
More
Webull provides a variety of real-time VCEL stock news. You can receive the latest news about Vericel through multiple platforms. This information may help you make smarter investment decisions.
About VCEL
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.